Subject characteristics (n = 15)
| Characteristic . | Value . |
|---|---|
| Median age, y (range) | 45 (20-68) |
| Patient sex, male/female, n | 10/5 |
| Donor type, n | |
| Matched related donor | 7 |
| Matched unrelated donor | 8 |
| Graft source, n | |
| Peripheral blood | 13 |
| Bone marrow | 2 |
| Diagnosis, n | |
| Acute lymphoblastic leukemia | 3 |
| Acute myeloid leukemia | 3 |
| Chronic myeloid leukemia | 2 |
| Chronic lymphocytic leukemia | 1 |
| Mantle cell lymphoma | 1 |
| Multiple myeloma | 1 |
| Non-Hodgkin lymphoma | 1 |
| Polycythemia vera/myelofibrosis | 1 |
| Sezary syndrome | 1 |
| Systemic lupus erythematosus | 1 |
| Median days status after transplantation at enrollment (range) | 1270 (100-4334) |
| Median no. of secondary therapies before study enrollment (range) | 3 (2-5) |
| cGVHD primary therapy, n | |
| Prednisone | 13 |
| Prednisone/cyclosporine | 2 |
| cGVHD secondary therapies, n | |
| Cyclosporine | 4 |
| Extracorporeal photopheresis | 8 |
| Tacrolimus | 6 |
| Mycophenolate mofetil | 5 |
| Pentostatin | 1 |
| Plaquenil | 1 |
| Rituximab | 5 |
| Daclizumab | 1 |
| cGVHD organ involvement upon study enrollment, n | |
| Skin/connective tissue | 13 |
| Oropharynx | 12 |
| Liver (total bilirubin) | 0 |
| Liver (AST, ALT, alkaline phosphatase) | 7 |
| Esophagus/lower GI | 7 |
| Ocular | 9 |
| Lung | 1 |
| Characteristic . | Value . |
|---|---|
| Median age, y (range) | 45 (20-68) |
| Patient sex, male/female, n | 10/5 |
| Donor type, n | |
| Matched related donor | 7 |
| Matched unrelated donor | 8 |
| Graft source, n | |
| Peripheral blood | 13 |
| Bone marrow | 2 |
| Diagnosis, n | |
| Acute lymphoblastic leukemia | 3 |
| Acute myeloid leukemia | 3 |
| Chronic myeloid leukemia | 2 |
| Chronic lymphocytic leukemia | 1 |
| Mantle cell lymphoma | 1 |
| Multiple myeloma | 1 |
| Non-Hodgkin lymphoma | 1 |
| Polycythemia vera/myelofibrosis | 1 |
| Sezary syndrome | 1 |
| Systemic lupus erythematosus | 1 |
| Median days status after transplantation at enrollment (range) | 1270 (100-4334) |
| Median no. of secondary therapies before study enrollment (range) | 3 (2-5) |
| cGVHD primary therapy, n | |
| Prednisone | 13 |
| Prednisone/cyclosporine | 2 |
| cGVHD secondary therapies, n | |
| Cyclosporine | 4 |
| Extracorporeal photopheresis | 8 |
| Tacrolimus | 6 |
| Mycophenolate mofetil | 5 |
| Pentostatin | 1 |
| Plaquenil | 1 |
| Rituximab | 5 |
| Daclizumab | 1 |
| cGVHD organ involvement upon study enrollment, n | |
| Skin/connective tissue | 13 |
| Oropharynx | 12 |
| Liver (total bilirubin) | 0 |
| Liver (AST, ALT, alkaline phosphatase) | 7 |
| Esophagus/lower GI | 7 |
| Ocular | 9 |
| Lung | 1 |
AST indicates aspartate aminotransferase; and ALT, alanine aminotransferase.